Home > Boards > US Listed > Medical - Equipment > Tandem Diabetes Care Inc (TNDM)

Per TNDM 8-k dated 6-09-2019:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 176
Posts 15,518
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2019 5:13:55 PM
Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Techno... Business Wire - 12/13/2019 1:36:00 PM
Tandem Diabetes Care Announces Health Canada Approval of t:slim X2 Insulin Pump with Basal-IQ Predictive Low-Glucose Suspend ... Business Wire - 11/20/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2019 4:25:50 PM
Tandem Diabetes Care Announces Upcoming Conference Presentations Business Wire - 11/8/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/6/2019 5:14:20 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2019 4:20:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:15:01 PM
Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance Business Wire - 11/4/2019 4:05:00 PM
2019 Beyond Type Run Team to Race the TCS New York City Marathon Using Basal-IQ Technology from Tandem Diabetes Care Business Wire - 11/1/2019 4:15:00 PM
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technolog... Business Wire - 10/30/2019 4:05:00 PM
Tandem Diabetes Care Announces NEJM Publication of Landmark Study Demonstrating Increased Time-In-Range with the t:slim X2 In... Business Wire - 10/16/2019 5:15:00 PM
Tandem Diabetes Care Up 10%; To Work With Abbott Dow Jones News - 10/15/2019 10:45:00 AM
Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management PR Newswire (US) - 10/15/2019 8:00:00 AM
Tandem Diabetes Care to Announce Third Quarter 2019 Financial Results on November 4, 2019 Business Wire - 10/14/2019 4:05:00 PM
Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes ... Business Wire - 9/18/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 4:20:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2019 7:28:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2019 4:19:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/29/2019 7:31:35 PM
Tandem Diabetes Care Announces Upcoming Conference Participation and Presentations Business Wire - 8/29/2019 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/28/2019 4:10:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 4:13:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/13/2019 4:54:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2019 6:54:58 PM
north40000 Member Level  Monday, 06/10/19 02:55:11 PM
Re: None
Post # of 276 
Per TNDM 8-k dated 6-09-2019:

Tandem Diabetes Care, Inc. issued a press release announcing results from two studies of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology. Details from the two studies, which included data from Protocol 3 of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop trial (DCLP3), and interim data from the Freelife Kid AP study, were presented on June 9, 2019 at the 79th Scientific Sessions of the American Diabetes Association.

PODD technology in combination with TNDM pump for young T1-D, said to delay development of T1-D. Very early in clinical trial.

**************************

"Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California. The study demonstrated that the investigational Omnipod Horizon System performed well and was safe for up to four days of use in children as young as two years old with type 1 diabetes.1

The study was conducted in a supervised hotel setting under free-living conditions with unrestricted meals and daily exercise and included pediatric participants between two and six years old. The study was preceded by seven days of their usual therapy at home with continuous glucose monitoring. Study participants spent significantly less time in hyperglycemia (=250 mg/dL), spent significantly more time in the target glucose range (70-180 mg/dL), and had better overnight glycemic control compared to their usual therapy, which is in line with the positive performance observed in earlier studies including older pediatric, adolescent and adult study participants. During the study, glucose control was maintained in the target range for 73% of the time overall and 85% of the time during the overnight period. The percentage of time spent in the hypoglycemic range (<70 mg/dL) was very low, at 2.9% overall and 2.0% overnight. The investigational Omnipod Horizon System includes unique features that allow diabetes management to be customized by adjusting the target blood glucose levels and insulin delivery....[more]

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist